Less than three years after debuting on the New York Stock Exchange in an initial public offering, Agiliti is leaving the ...
Perhaps Minerva Neurosciences should have taken a page from the tale of Arachne: Never boast that you know better than the ...
The president of BD’s life sciences division, Dave Hickey, is officially planning his retirement, with the calendar marked ...
The new device—dubbed KnowU—builds on the Generation 1 prototype that Know Labs debuted last summer. In the months since, the ...
After a hard few years, biopharma is as lean as ever, with pipelines shaved down so companies can stay afloat. But what if ...
Janux Therapeutics’ executives aren’t the only ones celebrating positive interim phase 1 data from two tumor-focused candidates, with analysts touting their blockbuster potential and investors ...
As Denali Therapeutics narrows in on large molecule biotherapeutics, the company is reorganizing, laying off an undisclosed ...
Johnson & Johnson is closing a nearly 200,000 square-foot R&D outpost in Brisbane, California, less than 18 months after it ...
Boehringer Ingelheim has made progress with its metabolic dysfunction-associated steatohepatitis (MASH) treatment, linking ...
Gilead placed its “best and final” offer to buy CymaBay on Jan. 30: $32.50 per share in cash. But the biotech’s board wanted ...
Philips is taking another step closer to radiation-free surgery, with a new fiber-optic-powered system designed to help ...
Novo Nordisk is getting sticky, coming together with Neomorph in a new licensing pact worth up to $1.46 billion across ...